of direction Amneal's made is strong. brother's Thank you, the We excited point foundation. see by on the my by and reiterating opportunities fundamentally to generic build start August the to Chirag. about to about will the are I we our year enthusiasm improvements started and of grow repeating business. like end have we start the our strong would at since I business
of file deep XXX pipeline over a products developing. still are products and marketed have We we once and
high products including reputation have worked We across topicals injectables, quality dosage hard producing of earn to complex and variety a of our liquids. transdermal, forms
which been quality priority us. a extremely our we of always track And service, customer has record proud are in for impeccable and
competition years, the in to While increased power over major across at the gross level Amneal the we we last compression saw buying industry unacceptable. and declines industry-wide of contributed of when few as CO-CEOS headwinds took the over was margin concentration
ultimately soon plus We as margin structure improve in of efforts our possible. margin the in gross target generic to our have been laser reach as segment focused and our percent XX
on begun already initiatives. have We these executing
have more structures. India, sites across improved oversaw manufacturing many infrastructure. oral cost lower transfer value our we have First, in We solid of our to plant which competitive utilization the products
on already year. won half additional proactively absorption our liquids, rings plant complex and our improved for the volume we for this awards a transdermal, of mentioned, will injectables at which increased material business has alone, have products the Chirag incremental year utilization We products, second including level impact in have which base have and as XX last
Second, we organization. the manage strengthen chain to and have taken cost our across supply steps
inventory needs, are addressed ensure and have delivering We inefficiencies to customers seeing their results. our which rates lower obsolescence. diligently already of products And expect working the with to to our are we right we are we mix of operational meet
chain significantly penalties our failures in than will These affect lower quarter entire forward. were Our three. supply supply going help efforts competitive and position to ensure four quarter the
Third, products months. value have including next rejoining previously first and to we high over products four to high the market version would XX launched. generic high NuvaRing you get we Carafate which August, Since of continue We margin told successfully are and at approved launch value, already least XX opportunities. XX we in to launched
with as As increase margins competition, we more limited our naturally products launch will well.
pursuit industry. in-house the have in We When some highest this manufacturing bringing focus we CMOS. we of a and on a reliance excellence. in including relentless we renewed ran of areas of reducing cost margins all our reduction Amneal, operational previously on Finally, had through accomplished the gross business
finance, leveraging the forward beginning. points XXXX. we It to network an of our -- took pleased over a four our So far achieved is are a and we to suppliers. four coordination XXX result And we the isn't generic I upon. is and this just just in cross reliable And this chain expansion process supply with of outlined, from And scalability August are customers. constant date. the three look and we one pleased which end initiative quarter direct gross to strengthening this have our margin quarter forecasting, basis we building believe and include buckets and also results is of with improving operations, Since
Now turning to R&D.
R&D any the pipeline as molecule the The not is engine within of of company generics. selection pharmaceutical ROI ever-changing successfully growth. not on with high-value of quantity as products for that landscape quality the acknowledge we be small our with it, needs industry, for launch to And to well the the is We spend. our to this execute used especially ability As and generic be. have the thoughtful be what product and it to focus given
in expect We and XX of market to are potential XX opportunities first as many file to XXXX well. products to these
which manufacturing waiting our And unlike in FDA better our have pipeline. on in development and products economics complex for XX product development of products. the We and approval expertise have many the we on us in reduces pipeline products gives XX and competitors, reliance parties high-value third both
And we R&D utilize opportunities. pursue to infrastructure have and just regulatory excellent begun to ex-US
of can global internationally right. that our process process imagine, hurdle geographically getting products with is and the drugs regulatory R&D. you As the many large launching starts expanding have We of of a recognize opportunity
as collaboration opportunity on drug this significant our ROI forward we augmenting and people and begun will continue changed sure to resources right Pharma the have already Fosun with have opportunity. existing have Generic We see may and with team we we execute we development our projects. but high move make to
Turning out specialty franchise. our
going to scalable opportunities segment. of It and see gross part meaningful foundation R&D across is to and a significant value solid, the in our specialty. expect creation significant and margin forward amount of budget our a a have specialty business allocate infrastructure and we We for
this grow about our continue we product very leveraging be to thoughtful business, and will infrastructure. existing As we selection
several We pipeline in assets. continue key to selectively invest
expect data Phase pivotal program significant versus top-line for immediate Xb development studies, data we half the combination release from in XXXX. from IPX-XXX showed move our Phase first carbidopa-levodopa X over statistically Xa continues recently which presented of key previous endpoints. Our forward to We study and improvement and
do Rytary. we We it with product about are to Parkinson's what have this disease the what beyond excited potential improve of and the for done patients could lives
expectation begin commercialization to than current later Our no XXXX. is
with which agreement BioSciences expands we neuromuscular Chirag disorder. entered licensing our Kashiv earlier, CNS into alluded in into As pipeline also November a
of agreement, this rights exclusive treatment of the now Amneal Gravis. part commercialization the Myasthenia K-XXX new drug As application within the US has and to of for
file to end by XXXX. expect of We this
version Avastin. are additional we Neulasta candidates products. pipeline. Neupogen, working For add actively Biosimilar biosimilars, the currently have and three And to in of
care and focus current the our to with time new in at oncology sales of Our we supplement and plan managed operations commercialization, marketing. focused resources is existing and commercial oncology
early market. it's become fully While to key we in the one days, biosimilar expect of the players US
development specialty leverage commercialization to and our assets In summary, we existing more where adding we forward can capabilities. look
Before continued I turn Todd? want employees, the that call customers over suppliers support. to thank to all and Todd, I for
